BioSpace News Archive

Policy

FDA Action Alert: Fennec, Gilead/Kite, Deciphera and Jazz/PharmaMar

Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.

August 6, 2020
·
4 min read
·
Mark Terry
BioCapital

Clinical Catch-Up: August 3-7

It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

August 6, 2020
·
8 min read
·
Mark Terry
Business

Could Obesity Be Contributing to Severe Cases of COVID-19?

Although obesity is a known risk factor for death from many conditions, such as cardiovascular disease, experts are now wondering how COVID-19 may impact those who fall into this category.

August 6, 2020
·
2 min read
·
Krystle Vermes
Business

BioSpace Movers & Shakers, Aug. 7

Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers.

August 6, 2020
·
5 min read
·
Alex Keown
Genetown

Tarveda’s Phase II Miniature Drug Conjugates Deliver Better Targeting, Less Toxicity than ADCs

Tarveda Therapeutics is advancing its miniature drug conjugates into Phase IIa trials, using a platform that combines the best aspects of small molecules and antibody drug conjugates while addressing their deficiencies.

August 6, 2020
·
4 min read
·
Gail Dutton
Drug Development

Octapharma Uses IVIG as Potential Treatment for COVID-19

Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.

August 6, 2020
·
4 min read
·
Alex Keown
Policy

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure

Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung

August 6, 2020
·
7 min read
Vifor Pharma Group Reports Continued Growth in H1 2020

Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic.

August 6, 2020
·
10 min read
Drug Development

Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL

Nordic Nanovector ASA announces that, following a planned interim analysis of the PARADIGME Phase 2b pivotal trial of Betalutin® in patients with relapsed/refractory follicular lymphoma, the Independent Review Committee has recommended Nordic Nanovector to focus on one dosage arm to completion.

August 6, 2020
·
5 min read
Deals

Nolato acquires US-based medtech manufacturer with annual sales of approximately SEK 1.8 billion

Nolato has signed an agreement to acquire US-based GW Plastics. The company, which was founded in 1955, has annual sales of approximately SEK 1.8 billion and an EBITA margin of around 7%.

August 6, 2020
·
4 min read